Vivoryon Therapeutics Management
Management criteria checks 2/4
Vivoryon Therapeutics' CEO is Frank Weber, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is €528.32K, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €66.54K. The average tenure of the management team and the board of directors is 6.2 years and 1.9 years respectively.
Key information
Frank Weber
Chief executive officer
€528.3k
Total compensation
| CEO salary percentage | 16.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 6.2yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully
Dec 05
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€31m |
| Mar 31 2024 | n/a | n/a | -€30m |
| Dec 31 2023 | €528k | €86k | -€28m |
Compensation vs Market: Frank's total compensation ($USD547.48K) is about average for companies of similar size in the Dutch market ($USD458.49K).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
CEO
Frank Weber (64 yo)
1.3yrs
Tenure
€528,320
Compensation
Dr. Frank T. Weber M. D. has been Chief Medical and Development Officer (CMDO) of Vivoryon Vivoryon Therapeutics N. V. (formerly known as Vivoryon Therapeutics AG & Probiodrug AG) since September 1, 2019....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board | 1.3yrs | €528.32k | 0.13% € 66.5k | |
| CSO & Investor Relations Officer | 1.3yrs | €405.12k | no data | |
| Chief Business Officer | 6.2yrs | €923.00k | no data | |
| Director of Investor Relations & Communications | no data | no data | no data | |
| Co-Founder & Advisor | no data | €222.11k | no data | |
| Advisor | no data | €319.20k | no data |
6.2yrs
Average Tenure
55yo
Average Age
Experienced Management: VVY's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board | 1.3yrs | €528.32k | 0.13% € 66.5k | |
| CSO & Investor Relations Officer | 1.3yrs | €405.12k | no data | |
| Chief Business Officer | no data | €923.00k | no data | |
| Independent Non-Executive Chairman | no data | €246.00k | 1.36% € 696.6k | |
| Independent Non-Executive Director | no data | €236.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | €337.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | €224.00k | 0.0038% € 2.0k |
1.9yrs
Average Tenure
55yo
Average Age
Experienced Board: VVY's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 15:49 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivoryon Therapeutics N.V. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |
| Lucy-Emma Mary Codrington-Bartlett | Jefferies LLC |
| Christian Ehmann | Warburg Research GmbH |